MedTrace Logo

Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors

NCT06027983 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-09-23

No results posted yet for this study

Summary

This phase Ib study aims to assess the safety and feasibility of combination of chimeric receptor T cells with trastuzumab in patients with HER2+ solid tumors, with further expansion of study population in HER2+ metastatic breast cancer once safety has been established.

Conditions

  • HER2+ Advanced Breast Cancer
  • Other Solid Tumors

Interventions

DRUG

Chimeric receptor T-cells + Trastuzumab

Chimeric receptor T-cells will be administered by infusion. Trastuzumab will be administered intravenously.

DRUG

Fludarabine and Cyclophosphosphamide

3-day chemotherapy regimen of fludarabine and cyclophosphamide for lymphodepletion

Sponsors & Collaborators

  • National University Hospital, Singapore

    lead OTHER

Principal Investigators

  • Soo Chin Lee · National University Hospital, Singapore

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-11-01
Primary Completion
2026-12-31
Completion
2027-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06027983 on ClinicalTrials.gov